The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2024 | Biomarker identification in NSCLC treated with neoadjuvant chemo-IO
Yulong Chen, MD, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China, discusses research on biomarkers associated with clinical outcomes in patients with stage II/III non-small cell lung cancer (NSCLC) treated with neoadjuvant pembrolizumab and chemotherapy. Whole transcriptome sequencing revealed that baseline pathological complete response (pCR) tumors exhibited upregulated immunomodulatory genes, while post-surgical samples showed positive immune regulation and reduced tumor progression markers. The study identified key biomarkers, which correlate with survival outcomes. This interview took place at the 2024 World Conference on Lung Cancer (WCLC) in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
